ADIAL PHARMACEUTICALS, INC.

ADILSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1513525

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Research and Development Expense	$3.2M	$1.3M	$2.0M	$8.4M	$5.9M
Operating Expenses	$8.3M	$6.9M	$10.9M	$19.3M	$10.9M
Operating Income (Loss)	-$8.3M	-$6.9M	-$10.9M	-$19.3M	-$10.9M
Nonoperating Income (Expense)	-$4.9M	-$113.9K	$63.3K	-$228.7K	$35.0K
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$13.2M	-$7.0M	-$10.8M	-$19.5M	-$10.9M
Income Tax Expense (Benefit)	—	—	—	-$94.1K	-$94.1K
Net Income (Loss) Attributable to Parent	-$13.2M	-$5.1M	-$12.7M	-$19.4M	-$10.9M
Earnings Per Share, Basic	-$68.01	-$3.60	-$12.71	-$1.04	—
Earnings Per Share, Diluted	-$68.01	-$3.60	-$12.71	-$1.04	—

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$5.0M	$4.7M	$5.7M	$7.5M	$5.5M
Assets, Current	$4.1M	$3.2M	$4.8M	$6.5M	$5.1M
Cash and Cash Equivalents, at Carrying Value	$3.8M	$2.8M	$4.0M	$4.4M	$4.4M
Liabilities	$975.9K	$653.1K	$2.5M	$4.0M	$1.5M
Liabilities, Current	$975.9K	$653.1K	$1.8M	$2.7M	$1.5M
Accounts Payable, Current	$250.1K	$103.3K	$276.4K	$286.2K	$648.7K
Stockholders' Equity Attributable to Parent	$4.1M	$3.3M	$3.5M	$4.0M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$6.9M	-$6.8M	-$11.2M	-$11.9M	-$7.6M
Net Cash Provided by (Used in) Investing Activities	$150.0K	$1.5M	$1.5M	-$34.0K	-$350.0K
Net Cash Provided by (Used in) Financing Activities	$7.8M	$4.1M	$9.1M	$13.6M	$5.6M
Payments to Acquire Property, Plant, and Equipment	—	—	—	$64.6K	$64.6K
Payments for Repurchase of Common Stock	—	$1.7K	$1.7K	—	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)